The 120-basis-point gross margin expansion over eight quarters, alongside operating margin moving from 0.7% to 1.1%, suggests structural mix improvement rather than cyclical relief, which may reflect the higher-margin Medical segment and fee-for-service mix cited in segment disclosures. However, the gap between gross margin gains and the roughly 0.6% net margin implies that interest expense, tax, and non-recurring items are absorbing most of the operating leverage, so investors should anchor on operating and gross profit rather than net margin when assessing Cardinal Health's true earning power.

A ROIC range of this magnitude against a consistently sub-1% net margin indicates the denominator — invested capital — is moving violently with inventory and payables rather than the earnings base itself, making the headline 23.4% look better supported than it likely is. Because goodwill has tripled to roughly $13.6 billion following acquisitions, the capital base against which returns are measured may be overstated or mismatched with productive assets, so the sustainability of these returns warrants further investigation before they are treated as evidence of a moat.

The structurally negative cycle, built on inventory turns of 26-29 days and DPO near two months, appears to represent genuine supplier and customer leverage consistent with oligopoly distribution economics, and it explains why operating cash flow can vastly exceed net income in favorable quarters. The flip side is that asset turnover has drifted down from 1.31 to 1.12, suggesting the acquisition-driven asset base is growing faster than revenue throughput, so efficiency gains on working capital may be partially offset by a heavier fixed-asset and intangible base.

Coverage has been far more uneven than the latest reading implies — swinging from 4.9x in fiscal 2026 Q3 to above 17x in earlier quarters — so the apparent comfort depends heavily on the quarter's working-capital cash timing rather than a stable earnings cushion. With debt-to-EBITDA around 9.6x and no reported debt-to-equity ratio given the negative equity position, refinancing conditions and lender appetite may matter more than operating risk here, and investors should monitor whether acquisition spending continues to consume cash faster than operations generate it.

The forward multiples of 11.6x EV/EBITDA and 11.8x P/FCF imply the market is pricing continued normalization rather than a fresh growth re-rating, which appears reasonable given the decelerating revenue trend toward 6% quarterly growth from 22% a year earlier. The 0.21x price-to-sales figure should be treated as uninformative for this model since revenue includes the cost of distributed drugs, and the apparent discount versus McKesson's trailing P/E may largely reflect earnings-quality differences rather than a genuine valuation gap worth exploiting.